The fight against new types of influenza virus

Biotechnology Journal

Volumn 1, Issue 12, 2006, Pages 1381-1392

  Romanova, Julia ^a  

^a Avir Green Hills Biotechnology AG   (Austria)

Author keywords

Avian; Influenza; Vaccine; Virus

Indexed keywords

ANTIVIRALS; AVIAN; CATASTROPHIC CONSEQUENCES; CONTAMINATED ENVIRONMENT; HONG-KONG; HUMAN POPULATION; INFLUENZA; INFLUENZA VIRUS; SOUTHEASTERN CHINA; VIRULENCE FACTORS; WILD BIRDS;

VACCINES;

VIRUSES;

INFLUENZA VACCINE;

ANIMAL; AVIAN INFLUENZA; BIRD; HUMAN; INFLUENZA; METHODOLOGY; REVIEW; VACCINATION;

ANIMALS; BIRDS; HUMANS; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 39049187085     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200600159     Document Type: Review

References (76)

1. Reid, A. H., Taubenberger, J. K., Fanning, T. G., Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. Nat. Rev. Microbiol. 2004, 2, 909-914.
2. Brownlee, G. G., Fodor, E., The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356, 1871-1876.
3. Gambaryan, A., Yamnikova, S., Lvov, D., Tuzikov, A. et al., Receptor specificity of influenza viruses from birds and mammals: new data on involvement of the inner fragments of the carbohydrate chain. Virology 2005, 334, 276-283.
4. Gambaryan, A. S., Tuzikov, A. B., Bovin, N. V., Yamnikova, S. S. et al., Differences between influenza virus receptors on target cells of duck and chicken and receptor specificity of the 1997 H5N1 chicken and human influenza viruses from Hong Kong. Avian Dis. 2003, 47, 1154-1160
5. Subbarao, K., Klimov, A., Katz, J., Regnery, H. et al., Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279, 393-396.
6. Matrosovich, M., Zhou, N., Kawaoka, Y., Webster, R., The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J. Virol. 1999, 73, 1146-1155.
7. Katz, J. M., Lim, W., Bridges, C. B., Rowe, T. et al., Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J. Infect. Dis. 1999, 180, 1763-1770.
8. Cauthen, A. N., Swayne, D. E., Schultz-Cherry, S., Perdue, M. L. et al., Continued circulation in China of highly pathogenic avian influenza viruses encoding the hemagglutinin gene associated with the 1997 H5N1 outbreak in poultry and humans. J. Virol. 2000, 74, 6592-6599.
9. Guan, Y., Peiris, J. S., Lipatov, A. S., Ellis, T. M. et al., Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc. Natl. Acad. Sci. USA 2002, 99, 8950-8955.
10. Chen, H., Li, Y., Li, Z., Shi, J. et al., Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China. J. Virol. 2006, 80, 5976-5983.
11. Olsen, B., Munster, V. J., Wallensten, A., Waldenstrom, J. et al., Global patterns of influenza a virus in wild birds. Science 2006, 312, 384-388.
12. Kuiken, T., Rimmelzwaan, G., van Riel, D., van Amerongen, G. et al., Avian H5N1 influenza in cats. Science 2004, 306, 241.
13. Smith, G. J., Naipospos, T. S., Nguyen, T. D., de Jong, M. D. et al., Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology 2006, 350, 258-268.
14. Chen, H., Smith, G. J., Li, K. S., Wang, J. et al., Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc. Natl. Acad. Sci. USA 2006, 103, 2845-2850.
15. Tran, T. H., Nguyen, T. L., Nguyen, T. D., Luong, T. S. et al., Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 2004, 350, 1179-1188.
16. Ungchusak, K., Auewarakul, P., Dowell, S. F., Kitphati, R. et al., Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 2005, 352, 333-340.
17. To, K. F., Chan, P. K., Chan, K. F., Lee, W. K. et al., Pathology of fatal human infection associated with avian influenza A H5N1 virus. J. Med. Virol. 2001, 63, 242-246.
18. Hatta, M., Gao, P., Halfmann, P., Kawaoka, Y., Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001, 293, 1840-1842.
19. Tumpey, T. M., Basler, C. F., Aguilar, P. V., Zeng, H. et al., Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005, 310, 77-80.
20. Cheung, C. Y., Poon, L. L., Lau, A. S., Luk, W. et al., Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002, 360, 1831-1837.
21. Obenauer, J. C., Denson, J., Mehta, P. K., Su, X. et al., Large-scale sequence analysis of avian influenza isolates. Science 2006, 311, 1576-1580.
22. Shinya, K., Hamm, S., Hatta, M., Ito, H. et al., PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology 2004, 320, 258-266.
23. Jefferson, T., Demicheli, V., Rivetti, D., Jones, M. et al., Antivirals for influenza in healthy adults: systematic review. Lancet 2006, 367, 303-313.
24. Hayden, F. G., Perspectives on antiviral use during pandemic influenza. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356, 1877-1884.
25. Harper, S. A., Fukuda, K., Uyeki, T. M., Cox, N. J. et al., Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2005, 54, 1-40.
26. Ziegler, T., Hemphill, M. L., Ziegler, M. L., Perez-Oronoz, G. et al., Low incidence of rimantadine resistance in field isolates of influenza A viruses. J. Infect. Dis. 1999, 180, 935-939.
27. Bright, R. A., Medina, M. J., Xu, X., Perez-Oronoz, G. et al., Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366, 1175-1181.
28. Regoes, R. R., Bonhoeffer, S., Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006, 312, 389-391.
29. Li, K. S., Guan, Y., Wang, J., Smith, G. J. et al., Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004, 430, 209-213.
30. Boivin, G., Goyette, N., Hardy, I., Aoki, F. et al., Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J. Infect. Dis. 2000, 181, 1471-1474.
31. Kashiwagi, S., Kudoh, S., Watanabe, A., Yoshimura, I., [Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza-placebo-controlled double-blind multicenter phase III trial]. Kansenshogaku Zasshi 2000, 74, 1062-1076.
32. Nicholson, K. G., Aoki, F. Y., Osterhaus, A. D., Trottier, S. et al., Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000, 355, 1845-1850.
33. Nicholson, K. G., Wood, J. M., Zambon, M., Influenza. Lancet 2003, 362, 1733-1745.
34. Puhakka, T., Lehti, H., Vainionpaa, R., Jormanainen, V. et al., Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand. J. Infect. Dis. 2003, 35, 52-58.
35. Gubareva, L. V., Matrosovich, M. N., Brenner, M. K., Bethell, R. C. et al., Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 1998, 178, 1257-1262.
36. Gubareva, L. V., Kaiser, L., Matrosovich, M. N., Soo-Hoo, Y. et al., Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 2001, 183, 523-531.
37. Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K. et al., Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364, 759-765.
38. Herlocher, M. L., Carr, J., Ives, J., Elias, S. et al., Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002, 54, 99-111.
39. Herlocher, M. L., Truscon, R., Elias, S., Yen, H. L. et al., Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 2004, 190, 1627-1630.
40. Carr, C. M., Kim, P. S., Flu virus invasion: halfway there. Science 1994, 266, 234-236.
41. Galama, J. M., [Avian influenza and oseltamivir; a retrospective view]. Ned. Tijdschr. Geneeskd. 2003, 147, 1100-1102.
42. Le, Q. M., Kiso, M., Someya, K., Sakai, Y. T. et al., Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437, 1108.
43. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int. 2006, 15, 21-30.
44. Clements, D. A., Langdon, L., Bland, C., Walter, E., Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch. Pediatr. Adolesc. Med. 1995, 149, 1113-1117.
45. Nicholson, K. G., Colegate, A. E., Podda, A., Stephenson, I. et al., Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357, 1937-1943.
46. Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A. et al., Crossreactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 2005, 191, 1210-1215.
47. Subbarao, K., Chen, H., Swayne, D., Mingay, L. et al., Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003, 305, 192-200.
48. Horimoto, T., Takada, A., Fujii, K., Goto, H. et al., The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 2006, 24, 3669-3676.
49. Wood, J. M., Major, D., Newman, R. W., Dunleavy, U. et al., Preparation of vaccines against H5N1 influenza. Vaccine 2002, 20 Suppl 2, S84-87.
50. Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T. et al., Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 2006, 354, 1343-1351.
51. Bresson, J. L., Perronne, C., Launay, O., Gerdil, C. et al., Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/ 1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367, 1657-1664.
52. Stephenson, I., Zambon, M. C., Rudin, A., Colegate, A. et al., Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 2006, 80, 4962-4970.
53. Alymova, I. V., Kodihalli, S., Govorkova, E. A., Fanget, B. et al., Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs. J. Virol. 1998, 72, 4472-4477.
54. Pau, M. G., Ophorst, C., Koldijk, M. H., Schouten, G. et al., The human cell line PER. C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001, 19, 2716-2721.
55. Treanor, J. J., Schiff, G. M., Couch, R. B., Cate, T. R. et al., Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis. 2006, 193, 1223-1228.
56. Wang, K., Holtz, K. M., Anderson, K., Chubet, R. et al., Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006, 24, 2176-2185.
57. Kodihalli, S., Goto, H., Kobasa, D. L., Krauss, S. et al., DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J. Virol. 1999, 73, 2094-2098.
58. Hoelscher, M. A., Garg, S., Bangari, D. S., Belser, J. A. et al., Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367, 475-481.
59. De Filette, M., Ramne, A., Birkett, A., Lycke, N. et al., The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24, 544-551.
60. Jegerlehner, A., Schmitz, N., Storni, T., Bachmann, M. F., Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004, 172, 5598-5605.
61. Fan, J., Liang, X., Horton, M. S., Perry, H. C. et al., Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22, 2993-3003.
62. Ernst, W. A., Kim, H. J., Tumpey, T. M., Jansen, A. D. et al., Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24, 5158-5168.
63. Kendal, A. P., Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur. J. Epidemiol. 1997, 13, 591-609.
64. Belshe, R. B., Gruber, W. C., Mendelman, P. M., Cho, I. et al., Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 2000, 136, 168-175.
65. Li, S., Liu, C., Klimov, A., Subbarao, K. et al., Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J. Infect. Dis. 1999, 179, 1132-1138.
66. Suguitan, A. L., McAuliffe, J., Mills, K. L., Jin, H. et al., Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 2006, 3.
67. Egorov, A., Brandt, S., Sereinig, S., Romanova, J. et al., Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J. Virol. 1998, 72, 6437-6441.
68. Garcia-Sastre, A., Egorov, A., Matassov, D., Brandt, S. et al., Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998, 252, 324-330.
69. Ferko, B., Stasakova, J., Romanova, J., Kittel, C. et al., Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J. Virol. 2004, 78, 13037-13045.
70. Bracci, L., Canini, I., Puzelli, S., Sestili, P. et al., Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 2005, 23, 2994-3004.
71. Swayne, D. E., Beck, J. R., Kinney, N., Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine. Avian Dis. 2000, 44, 132-137.
72. Swayne, D. E., Garcia, M., Beck, J. R., Kinney, N. et al., Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert. Vaccine 2000, 18, 1088-1095.
73. Lee, C. W., Senne, D. A., Suarez, D. L., Effect of vaccine use in the evolution of Mexican lineage H5N2 avian influenza virus. J. Virol. 2004, 78, 8372-8381.
74. Qiao, C. L., Yu, K. Z., Jiang, Y. P., Jia, Y. Q. et al., Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Avian Pathol. 2003, 32, 25-32.
75. Park, M. S., Steel, J., Garcia-Sastre, A., Swayne, D. et al., From the Cover: Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease. Proc. Natl. Acad. Sci. USA 2006, 103, 8203-8208.
76. Veits, J., Wiesner, D., Fuchs, W., Hoffmann, B. et al., Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc. Natl. Acad. Sci. USA 2006, 103, 8197-8202.